Outcomes according to acute or chronic GVHD at initial presentation. Cumulative incidence of (A) nonrelapse mortality and (B) recurrent malignancy and (C) overall survival are shown for patients who presented initially with chronic GVHD according to NIH criteria (n = 388; —) compared with those who presented initially with late acute GVHD (n = 352; ). In all 3 panels, progression to NIH chronic GVHD was treated as a competing risk for patients who presented initially with late acute GVHD.